sanofi_hq__boetie_hall_web

EU approves Aubagio for children living with MS

pharmafile | June 21, 2021 | News story | Sales and Marketing  

The EU has approved Aubagio (teriflunomide) for the treatment of paediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS) based on data from the Phase III TERIKIDS study.

The approval makes Aubagio as the first oral multiple sclerosis (MS) therapy for first-line treatment of children and adolescents with MS in the European Union.

Erik Wallström, Therapeutic Area Head, Neurology Development at Sanofi Genzyme, said: “Paediatric multiple sclerosis remains an area of significant unmet medical need.

Advertisement

“The European approval of Aubagio in pediatrics means young people with MS have a new treatment option, and importantly − one that can offer meaningful improvement in managing this serious disease.”

MS is a chronic neurodegenerative disease in which a person’s immune system causes damage to the brain and spinal cord.

It affects an estimated 2.8 million people around the world, with children and adolescents representing at least 30,000 of those impacted.

The symptoms of MS can impact all aspects of a young person’s life from physical health to social development and self-esteem.

Pediatric MS is a rare condition and onset follows a relapsing-remitting disease course in 98 percent of paediatric patients. Compared with adult-onset MS, paediatric patients often present with higher relapse rates and a greater lesion burden.  

Due to the earlier onset of disease, irreversible disability and secondary progression often occur at an earlier age than with adult counterparts.

Lilly Subbotin

Related Content

No items found
The Gateway to Local Adoption Series

Latest content